ECEmi Caywood

Emi Caywood

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Emi Caywood has a total of 240 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Radiation‐Free Haploidentical Transplantation With PTCy and Extended Abatacept in Pediatric Nonmalignant Disorders

    by Thomas Pfeiffer, Alexander Ngwube, Rachel E. Granberg, Ian Snyder, Ginny Schulz, Allison A. King, Melissa Mavers, Robert J. Hayashi, Jeffrey J. Bednarski, Yvonne Suessmuth, et al.

  • Comparative Effectiveness of Antibiotic Prophylaxis Regimens in Pediatric Acute Myeloid Leukemia

    by Catherine Aftandilian, Yimei Li, Kira O. Bona, Emi Caywood, Taumoha Ghosh, M. Monica Gramatges, Meret Henry, Craig Lotterman, Kelly Maloney, Tamara P. Miller, et al.

    Background: There are limited real‐world comparative effectiveness data on different antibiotic prophylaxis regimens of children receiving treatment for acute myeloid leukemia (AML). Procedure: We compared the effectiveness of third/fourth‐generation cephalosporin (cephalosporin) or quinolone prophylaxis with no antibiotic prophylaxis to prevent bacteremia during frontline AML therapy using an established cohort from 17 institutions. The prophylaxis regimen was at the discretion of the treating clinician. Secondary outcomes were Clostridioides difficile infection (CDI), time to next chemotherapy course, and mortality. Results: A total of 550 pediatric patients with AML contributed data from 1758 chemotherapy courses. Incident bacteremia was lower following cephalosporin and quinolone prophylaxis compared to no prophylaxis in post‐induction I chemotherapy courses (6.9% cephalosporin vs. 33.9% no prophylaxis, risk ratio [RR] 0.20, p < 0.01; 20.8% quinolone vs. 33.9% no prophylaxis, RR 0.61, p < 0.01). Reduction in bacteremia risk was greater with cephalosporin than with quinolone prophylaxis (RR 0.33, p < 0.01). CDI was rare and was not increased in those receiving prophylaxis (2.5% quinolone vs. 3.6% cephalosporin vs. 5.7% no prophylaxis; p = 0.05). Time to next course of chemotherapy was similar between groups except during intensification I, where patients receiving cephalosporin prophylaxis had a longer time to next chemotherapy (50 days for cephalosporin vs. 41 days for no prophylaxis, p < 0.01). Deaths during treatment were rare. Conclusions: Cephalosporin and quinolone prophylaxis reduced bacteremia without an increased risk of CDI. Additional work is needed to assess the differential impact of prophylaxis regimen on subsequent use of empiric therapy and development of resistance.

  • Open Access

    Newborn screening reduces survival disparities in SCID after stem cell transplant: A PIDTC report

    by Lena E. Winestone, Brent R. Logan, Xuerong Liu, Olatundun Williams, Elizabeth A. Dunn, Monica S. Thakar, Sharon A. Kidd, Talal Mousallem, Morna J. Dorsey, Richard J. O’REilly, et al.

    Winestone et al. demonstrate that in 796 children with SCID transplanted with nonsibling donors between 1982 and 2020, survival was 18.8% lower among Black patients, 14.4% lower among Asian/Pacific Islander patients, and 6.9% lower among Hispanic patients compared with non-Hispanic White patients (P < 0.01). Newborn screening for SCID mitigates wide disparities between Black and non-Hispanic White patients.


  • Factors Associated With Symptom Burden Among Pediatric Patients With Cancer

    by Adam P. Yan, L. Lee Dupuis, Catherine Aftandilian, Vibhuti Agarwal, Christina Baggott, Melissa P. Beauchemin, Scott M. Bradfield, Daniel Cannone, Emi H. Caywood, Nicole Crellin-Parsons, et al.

    PURPOSE: The objective was to identify factors associated with self-reported symptom burden measured using Symptom Screening in Pediatrics Tool (SSPedi) in pediatric patients with cancer. METHODS: This was a secondary analysis of a cluster randomized trial enrolling pediatric patients newly diagnosed with cancer. Twenty sites were randomized to routine symptom screening versus usual care. Intervention included thrice-weekly symptom screening with SSPedi, delivery of severely bothersome scores to health care teams, and implementation of locally adapted symptom management care pathways. Primary outcome was total SSPedi scores, 0 (no bothersome symptoms) to 60 (worst bothersome symptoms), obtained at baseline, week four, and week eight in 430 patients (n = 217 intervention and n = 213 usual care). We created a mixed linear regression model evaluating design (including time point), patient/guardian, and site characteristics for their associations with symptom burden after controlling for treatment assignment. RESULTS: SSPedi scores were significantly lower at weeks 4 and 8 compared with baseline ( P < .0001 overall), and at intervention versus control sites ( P < .0001). In the full model, males (estimate, –3.3 [95% CI, –4.6 to –2.0]; P < .0001) and sites with higher physician staffing ratios (each physician full-time equivalent per 100 new diagnoses estimate –0.20 [95% CI, –0.5 to 0.0]; P = .024) had significantly lower total SSPedi scores. CONCLUSION: Total symptom burden was reduced by time, intervention (symptom screening and care pathways), and greater physician staffing ratio. Females had higher symptom burden. These data may inform programmatic implementation of routine symptom screening in pediatric patients with cancer.


  • Natural History of Morquio A Syndrome

    by Shunji Tomatsu, Kimberly Klipner, Marie Sahou, Jacky M. Guerrero‐Vargas, Stuart Mackenzie, Lauren Averill, Heidi Kecskemethy, Yasuhiko Ago, Shaukat Khan, Chris Church, et al.

    Mucopolysaccharidosis IVA (Morquio A) is a progressive lysosomal disorder caused by a deficiency of N‐acetylgalactosamine‐6‐sulfate sulfatase, resulting in the accumulation of glycosaminoglycans, primarily in cartilage and bone. The condition leads to skeletal dysplasia, impaired ossification, and growth imbalance, causing cervical compression, tracheal obstruction, hip dysplasia, and cardiopulmonary complications. Although existing natural history studies have clarified several aspects of disease progression, objective methods to quantify skeletal pathology and its functional impact remain limited. Standard endurance‐based assessments, including the 6‐min walk test, 3‐min stair climb, and spirometry, are variable and infeasible for young children, wheelchair‐dependent individuals, or patients with respiratory or postoperative limitations. Their dependence on motivation, training, and site‐specific differences restricts their value as reliable endpoints. Significant gaps persist in the objective evaluation of skeletal dysplasia progression and its functional impact. There remains an unmet need for non‐invasive, quantitative tools that capture multisystem involvement across the full phenotypic spectrum. Objective tools exist as we reported but have not been widely implemented or standardized, and data supporting their use as regulatory endpoints remain limited. Emerging longitudinal, multidisciplinary evaluations and surrogate biochemical biomarkers show potential to define disease severity, support prognosis, and serve as validated endpoints for therapeutic monitoring and surgical risk stratification. In conclusion, to address the limitations of prior studies, we propose a novel natural history program of innovative, non‐invasive assessments based on our compiled data. Such approaches may contribute to more consistent longitudinal data and help inform the development of clinical endpoints for emerging therapies.


  • Top Cited Papers
    Open Access

    Distinct biological subtypes of chronic GVHD after pediatric hematopoietic cell transplantation

    by Bernard Ng, Andrew C. Harris, Sayeh Abdossamadi, Geraldine Aubert, Rajinder Bajwa, Monica Bhatia, Henrique Bittencourt, Nataliya P. Buxbaum, Emi H. Caywood, Sonali Chaudhury, et al.

    Chronic graft-versus-host-disease (cGVHD) is the primary nonrelapse limitation to a successful hematopoietic cell transplantation and is largely treated as a single biological entity. We hypothesized that there exist different biological subtypes of cGVHD. Using the Applied Biomarkers of Late Effects of Childhood Cancer (ABLE) network database, which is derived from the largest pediatric cGVHD cohort worldwide, we applied clustering analysis to subtype patients with cGVHD from the ABLE1.0 and 2.0 studies (51 patients with cGVHD and 158 with non-cGVHD). We found 3 distinct cGVHD subtypes: cGVHD-1 was characterized by an effector memory T-cell, cytotoxic natural killer cell, and early precursor B-cell predominant pattern; cGVHD-2 was phosphatidylcholine, cytokine, and plasma cell predominant; and cGVHD-3 had more naïve CD4+ T cells and naïve regulatory T cells, had later onset, and was the only subtype with measurable T-cell receptor excision circles. We partially replicated these subtypes using metabolomic data from a separate pediatric cohort of the Children’s Oncology Group trial ASCT0031 (33 patients with cGVHD and 39 with non-cGVHD). Furthermore, cGVHD-1 was associated with serotherapy (predominantly antithymocyte globulin) exposure, and cGVHD-3 was associated with receiving peripheral blood stem cells from donors, total body irradiation, and no previous acute GVHD. cGVHD-2 was associated with liver involvement and cGVHD-2 and -3 with de novo cGVHD. Overall, none of the subtypes were closely associated with organ involvement. Contrasting each subtype against patients with non-cGVHD, the 3 subtypes shared common markers, all of which were used in our previous cGVHD diagnostic classifier. These findings suggest the presence of distinct biological subtypes of cGVHD that may help guide therapeutic strategies.


  • Real-world generalizability of clinical trial cytomolecular risk in pediatric acute myeloid leukemia: a report from the REAL-AML cohort

    by Daniel J Zheng, Gary Hettinger, Catherine Aftandilian, Kira Bona, Emi H Caywood, Anderson B Collier, Caitlin W Elgarten, Cody Gathers, Taumoha Ghosh, M Monica Gramatges, et al.

    Cytomolecular features critical for risk-stratified treatment determination in pediatric acute myeloid leukemia (AML) were expanded in Children’s Oncology Group (COG) Phase III trial AAML1831 based on previous trials. It remains unknown whether the cytomolecular risk profiles are generalizable to the real-world. We addressed this knowledge gap using a nationally representative real-world cohort of 913 pediatric AML patients. Distributions of cytomolecular risk profiles and individual markers were comparable for trial-enrolled and non-enrolled patients, as well as across social drivers of trial enrollment (race/ethnicity, language, insurance, acuity). Compared to patients with only favorable cytomolecular markers (4-year overall survival [OS] = 89.48%; 95% CI = 84.46% to 92.95%), patients with both favorable and unfavorable (hazards ratio [HR] = 2.49, 95% CI = 1.18 to 5.23), neutral (HR = 4.33, 95% CI = 2.75 to 6.82), and only unfavorable (HR = 5.80, 95% CI = 3.70 to 9.11) markers all had increased hazards of death. Cytomolecular risk informed by trial data appears to be generalizable to the real-world setting in pediatric AML.


  • Open Access

    Data from Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation

    by Aditi Dhir, Masanori Hayashi, Avery Bodlak, Javier Oesterheld, David M. Loeb, Leo Mascarenhas, Michael S. Isakoff, Eric S. Sandler, Scott C. Borinstein, Matteo Trucco, et al.

    Purpose:The combination of gemcitabine and docetaxel is often used to treat patients with recurrent osteosarcoma. Nab-paclitaxel has preclinical activity against osteosarcoma and is potentially less myelosuppressive than docetaxel. We conducted a prospective multi-institutional phase II trial combining gemcitabine and nab-paclitaxel for patients aged 12 to 30 years with recurrent osteosarcoma and measurable disease.Patients and Methods:A Simon’s two-stage design was used to test a 4-month progression-free survival (PFS-4) of 10% vs. 35%. Patients received nab-paclitaxel 125 mg/m2 and gemcitabine 1,000 mg/m2 weekly × 3 in 4-week cycles. Immunohistochemical analysis of archival tissue and serial assessment of circulating tumor cells (CTC) and circulating tumor DNA (ctDNA) using ultralow passage whole-genome sequencing were performed to identify potential biomarkers of response.Results:Eighteen patients received 56 total cycles (median 2, range 1–12). Two patients (11%) experienced confirmed partial response and six (33%) received >2 cycles. The PFS-4 was 28% (95% confidence interval, 13%–59%). Six patients required dose reductions and three patients were removed due to toxicities. All 18 patients had detectable CTCs and 10 had ctDNA identified. All eight patients with MYC amplification at study entry experienced disease progression.Conclusions:Gemcitabine and nab-paclitaxel demonstrated similar clinical activity and toxicity compared to previous retrospective reports utilizing gemcitabine and docetaxel in patients with recurrent osteosarcoma. Serial analysis of CTC and ctDNA was feasible in this prospective multi-institution study and provides preliminary data on the use of these assays in patients with relapsed disease.

  • Open Access

    Supplementary Table S3 from Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation

    by Aditi Dhir, Masanori Hayashi, Avery Bodlak, Javier Oesterheld, David M. Loeb, Leo Mascarenhas, Michael S. Isakoff, Eric S. Sandler, Scott C. Borinstein, Matteo Trucco, et al.

    Supplemental Table S3. Detailed ctDNA results over the course of the study.

  • Open Access

    Supplementary Table S1 from Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation

    by Aditi Dhir, Masanori Hayashi, Avery Bodlak, Javier Oesterheld, David M. Loeb, Leo Mascarenhas, Michael S. Isakoff, Eric S. Sandler, Scott C. Borinstein, Matteo Trucco, et al.

    Supplementary Table S1. Representativeness of Study Participants